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Despite the high degree of HIV-1 protease and reverse transcriptase (RT) mutation in the setting of antiretroviral
therapy, the spectrum of possible virus variants appears to be limited by patterns of amino acid covariation. We
analyzed patterns of amino acid covariation in protease and RT sequences from more than 7,000 persons infected with
HIV-1 subtype B viruses obtained from the Stanford HIV Drug Resistance Database (http://hivdb.stanford.edu). In
addition, we examined the relationship between conditional probabilities associated with a pair of mutations and the
order in which those mutations developed in viruses for which longitudinal sequence data were available. Patterns of
RT covariation were dominated by the distinct clustering of Type I and Type II thymidine analog mutations and the
Q151M-associated mutations. Patterns of protease covariation were dominated by the clustering of nelfinavir-
associated mutations (D30N and N88D), two main groups of protease inhibitor (PI)–resistance mutations associated
either with V82A or L90M, and a tight cluster of mutations associated with decreased susceptibility to amprenavir and
the most recently approved PI darunavir. Different patterns of covariation were frequently observed for different
mutations at the same position including the RT mutations T69D versus T69N, L74V versus L74I, V75I versus V75M,
T215F versus T215Y, and K219Q/E versus K219N/R, and the protease mutations M46I versus M46L, I54V versus I54M/L,
and N88D versus N88S. Sequence data from persons with correlated mutations in whom earlier sequences were
available confirmed that the conditional probabilities associated with correlated mutation pairs could be used to
predict the order in which the mutations were likely to have developed. Whereas accessory nucleoside RT inhibitor–
resistance mutations nearly always follow primary nucleoside RT inhibitor–resistance mutations, accessory PI-
resistance mutations often preceded primary PI-resistance mutations.
Citation: Rhee SY, Liu TF, Holmes SP, Shafer RW (2007) HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput Biol 3(5): e87. doi:10.1371/
journal.pcbi.0030087
Introduction
HIV-1 is a highly mutable pathogen. In the decades since it
entered human populations, it has accumulated extensive
sequence variation leading to the development of different
subtypes and recombinant forms [1]. Although the enzymatic
targets of therapy are among the most conserved parts of the
HIV-1 genome, these too can develop marked variation,
particularly in the setting of selective antiretroviral drug
pressure. Indeed, it is not uncommon for drug therapy to
select for protease and reverse transcriptase (RT) variants
containing substitutions at more than 10% of their amino
acids [2]. However, despite this high degree of mutation, the
spectrum of possible virus variants appears to be limited by
patterns of amino acid covariation.
In 2003, we published two studies that examined the extent
of covariation among RT and protease residues in the
presence and absence of antiretroviral therapy [3,4]. Despite
the relatively large size of the datasets in these studies—2,244
protease sequences and 1,210 RT sequences—there were
insufﬁcient data to examine patterns of covariation of
different mutations at the same position. As more sequence
data have become available, we are now analyzing covariation
among mutations (rather than positions) in protease and RT.
This expanded analysis uses a highly speciﬁc measure of
covariation, the Jaccard similarity coefﬁcient, and a multi-
dimensional scaling based on this coefﬁcient. In addition, we
examine the relationship between conditional probabilities
associated with a mutation pair and the order in which those
mutations develop in viruses for which longitudinal sequence
data are available.
Results
Protease
Protease sequences from 3,982 protease inhibitor (PI)–
naive individuals and from 3,475 PI-experienced individuals
were available for analysis. The PI-experienced individuals
had received a median of 1 PI (interquartile range, 1–3).
Jaccard similarity coefﬁcients and their standardized Z
scores were calculated for all pairs of mutations at different
positions present three or more times among the sequences
from PI-naive and PI-experienced individuals. Among 19,203
pairs of mutations from the PI-experienced individuals, 161
pairs were signiﬁcantly associated after adjusting for multiple
comparisons by controlling the family-wise error rate at
,0.01. Of these 161 pairs, 92 (57%) were positively associated
(Z . 5.1, unadjusted p , 4.4 3 10
 7) and 69 (43%) were
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 7).
Table 1 shows the Jaccard similarity coefﬁcients and condi-
tional probabilities of the 40 strongest positively associated
protease mutation pairs and the ten strongest negatively
associated protease mutation pairs. Table S1 shows the
complete list of 161 statistically signiﬁcant mutation pairs.
For the positively associated mutation pairs, Table 1 also
contains two columns with data on the temporal order in
which correlated mutations occurred in sequences with both
mutations from persons in which an earlier sequence was
available that contained only one of the two mutations. For
example, the ﬁrst row shows that among persons with both
I54V and V82A in whom an earlier sequence contained only
one of these two mutations was available, I54V occurred ﬁrst
in nine (26%) of 34 people, and V82A occurred ﬁrst in 25
(74%) of 34 people (p , 0.01). In contrast, the fourth row
shows that among persons with both A71V and L90M, each of
the mutations was as likely to occur ﬁrst (26 of 51 versus 25 of
51; p ¼ NS). Figure S1 plots the relationship between the log
of the ratio of the conditional probability of two mutations
versus the log of the ratio in which two mutations develop,
indicating that the conditional dependence between muta-
tions is highly correlated with the order in which the
mutations develop when they occur together (r
2 ¼ 0.56, p ,
0.001).
Among the 18 positively associated pairs in Table 1
containing a major and an accessory PI-resistance mutation
(as deﬁned in Methods), the accessory mutation appeared ﬁrst
more often in 12 of the 18 pairs. There were several striking
patterns of temporal association among these 18 pairs of
correlated major and accessory mutations. The major
mutation L90M preceded the accessory mutation G73S in
31 of 34 persons for whom temporal data were available. In
contrast, the accessory mutation L63P preceded L90M in 160
of 172 persons, and the accessory mutations L10I and A71V
preceded the major mutation I84V in 51 of 59 and 35 of 38
persons, respectively.
The Jaccard dissimilarity coefﬁcients associated with 595
pairs of 35 mutations were used for a multidimensional
scaling. The mutations included in this analysis were the 22
positively associated mutations in Table 1 and 13 additional
clinically relevant PI-resistance mutations (L10F, V32I, L33F,
I47V, I50V/L, F53L, I54L/M, Q58E, L76V, V82T, and N88S).
Figure 1 plots the mutations along axes representing the ﬁrst
two principal components. The ﬁrst principal component
accounted for 10% of the total inertia and separates the
nelﬁnavir-resistance mutations D30N and N88D from the
main group of PI-resistance mutations. The second principal
component accounted for 7% of the total inertia and
separates V82A-associated mutations (I54V, L24I, and
M46L) from L90M-associated mutations (M46I, G73S, and
I84V). Finally, the lower-left part of the ﬁgure contains a
cluster with seven of the 11 mutations recently reported to be
associated with phenotypic and clinical resistance to the
newest PI, darunavir (V32I, L33F, I47V, I50V, I54L/M, and
L76V).
At several positions, there was sufﬁcient data to contrast
covariation patterns for different mutations. For example,
M46I/L were each signiﬁcantly associated with L10I, L24I,
V32I, L33F, I54V, V82A, and L90M. However, M46I was
uniquely associated with F53L, G73S/T, V82F/T, I84V, and
N88S. I54V was signiﬁcantly associated with L10F, L24I, L33F,
M46I/L, G48V, F53L, V82A/F/T, I84V, and L90M. In contrast,
I54L/M were signiﬁcantly associated only with L33F, M46I,
I47V, I84V, and L90M. N88D was positively associated with
D30N and negatively associated with M46I, whereas N88S was
negatively associated with D30N and positively associated
with M46I. Of note, the divergent associations of different
mutations at positions 46 and 88 have previously been
reported by Hoffman and coworkers [5].
Among 7,131 pairs of mutations in sequences from PI-naive
persons, 65 pairs were signiﬁcantly associated (family-wise
error rate , 0.01; Table S2). All but three of the positive
associations among PI-naive persons were weaker (i.e., had a
lower Z score) than the positive associations among treated
persons in Table 1.
Reverse Transcriptase
RT sequences from 2,601 RT inhibitor–naive and from
5,188 RT inhibitor–experienced individuals were available for
analysis. The RT inhibitor experienced individuals had
received a median of three nucleoside RT inhibitors (NRTIs;
interquartile range, 2–4) and zero nonnucleoside RT inhib-
itors (NNRTIs; interquartile range, 0–1).
Jaccard similarity coefﬁcients and their standardized Z
scores were calculated for all pairs of RT mutations at
different positions present three or more times among the
sequences from RT inhibitor–experienced and –naive per-
sons. Among 65,624 pairs of mutations from the RT
inhibitor–experienced persons, 327 pairs were signiﬁcantly
associated after adjusting for multiple comparisons by
controlling the family-wise error rate at ,0.01. Of these 327
pairs, 213 (65%) were positively associated (Z . 5.2,
unadjusted p , 2 3 10
 7) and 114 (35%) were negatively
associated (Z , 5.0, unadjusted p , 5310
 7). Table 2 shows
the Jaccard similarity coefﬁcients and conditional probabil-
ities of the 40 strongest positively associated RT mutation
pairs and the ten strongest negatively associated RT mutation
pairs. Table S3 shows the complete list of 327 statistically
signiﬁcant RT mutation pairs.
Positively associated mutation pairs consisted primarily of
Type I or II thymidine analog mutations (TAMs; as deﬁned in
Methods); accessory NRTI mutations that occurred in
combination with Type I or II TAMs (K43E, E44D, V118I,
H208Y, D218E); and Q151M-associated mutations (V75I,
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Author Summary
The identification of which mutations in a protein covary has played
a major role in both structural and evolutionary biology. Covariation
analysis has been used to help predict unsolved protein structures
and to better understand the functions of proteins with known
structures. The large number of published genetic sequences of the
targets of HIV-1 therapy has provided an unprecedented oppor-
tunity to identify dependencies among mutations in these proteins
that can be exploited to design inhibitors that have high genetic
barriers to resistance. In our analysis, we identified many pairs of
covarying drug-resistance mutations in HIV-1 protease and reverse
transcriptase and organized them into clusters of mutations that
often develop in a predictable order. Inhibitors that are active
against early drug-resistant mutants are likely to be less prone to the
development of resistance, whereas inhibitors that are active against
fully evolved clusters of mutations may be useful drugs for salvage
therapy.
HIV-1 Amino Acid CovariationF77L, F116Y). Among the top 40 associated mutation pairs,
there were only three positive associations between Type I
and II TAMs (M41L, L210W, and T215Y with D67N). The
strongest signiﬁcant association between an NRTI and an
NNRTI mutation was between L74V and Y181C (J ¼ 0.17, Z ¼
8.9, unadjusted p , 1 3 10
 11). Of note, the associations
between the ﬁve accessory mutations listed above and Type I
and II TAMs have also previously recently been described by
Table 1. Forty Highest Positively Correlated Protease Mutation Pairs and Ten Highest Negatively Correlated Protease Mutation Pairs
from PI-Experienced Persons
Correlations Mut X Mut Y Association
a P(YjX) P(XjY) Temporal Order
b Mutation
Classifications
c
JJ RAND JSE Zp N X0!XY N0Y!XY
Positive
Correlations
54V 82A 0.51 0.11 0.02 23.8 0 0.73 0.63 9 25 Maj
30N 88D 0.59 0.04 0.03 21.0 0 0.62 0.91 13 2 Maj
35D 36I 0.40 0.15 0.01 17.8 0 0.55 0.60 57 19 Maj – Misc
71V 90M 0.38 0.17 0.01 15.8 0 0.59 0.51 26 25 Maj – Acc
10I 54V 0.34 0.14 0.01 14.8 0 0.39 0.69 35 14 Maj – Acc
10I 90M 0.38 0.19 0.01 14.8 0 0.54 0.56 31 34 Maj – Acc
10I 82A 0.34 0.15 0.01 14.5 0 0.42 0.65 28 25 Maj – Acc
71V 82A 0.34 0.14 0.01 14.4 0 0.45 0.57 15 27 Maj – Acc
54V 71V 0.32 0.13 0.01 14.2 0 0.60 0.41 16 29 Maj – Acc
10I 71V 0.36 0.18 0.01 14.1 0 0.48 0.58 40 31 Acc
20R 36I 0.29 0.07 0.02 14.1 0 0.89 0.30 3 47 Acc
77I 93L 0.34 0.20 0.01 11.8 0 0.54 0.47 26 36 Acc
46L 82A 0.25 0.07 0.02 11.7 0 0.68 0.28 1 17 Maj
73S 90M 0.21 0.07 0.01 11.5 0 0.87 0.22 3 31 Maj – Acc
36I 62V 0.30 0.16 0.01 11.3 0 0.50 0.43 39 29 Acc – Misc
84V 90M 0.23 0.09 0.01 11.2 0 0.70 0.26 3 44 Maj
46I 90M 0.26 0.13 0.01 10.6 0 0.57 0.33 18 44 Maj
10I 84V 0.22 0.09 0.01 10.5 0 0.25 0.69 51 8 Maj – Acc
62V 90M 0.30 0.18 0.01 10.1 0 0.48 0.45 47 28 Maj – Acc
71V 73S 0.19 0.06 0.01 10.0 0 0.21 0.73 24 4 Maj – Acc
20R 54V 0.20 0.06 0.01 9.5 0 0.54 0.24 7 16 Maj – Acc
63P 90M 0.38 0.29 0.01 9.4 0 0.40 0.89 160 12 Maj – Acc
54V 90M 0.24 0.14 0.01 9.3 0 0.53 0.31 14 41 Maj
46L 54V 0.20 0.06 0.01 9.2 0 0.53 0.24 11 10 Maj
90M 93L 0.31 0.20 0.01 9.2 0 0.49 0.45 19 73 Maj – Acc
24I 54V 0.17 0.04 0.01 9.0 0 0.71 0.18 3 2 Maj
36I 54V 0.23 0.12 0.01 9.0 0 0.32 0.45 35 22 Maj – Acc
24I 82A 0.16 0.04 0.01 8.9 0 0.75 0.17 0 7 Maj
10I 46I 0.24 0.13 0.01 8.8 0 0.30 0.53 57 22 Maj – Acc
20R 35D 0.17 0.07 0.01 8.8 0 0.64 0.19 1 53 Acc – Misc
46I 84V 0.20 0.08 0.01 8.8 0 0.27 0.43 21 13 Maj
71V 84V 0.19 0.09 0.01 8.4 0 0.22 0.54 35 3 Maj – Acc
20R 82A 0.17 0.06 0.01 8.3 0 0.53 0.20 10 22 Maj – Acc
10I 93L 0.30 0.20 0.01 8.2 2E-16 0.47 0.44 21 67 Acc
10I 62V 0.28 0.18 0.01 8.0 1E-15 0.41 0.46 38 46 Acc – Misc
35D 37D 0.19 0.10 0.01 7.9 2E-15 0.24 0.49 25 7 Misc
48V 82A 0.13 0.03 0.01 7.8 6E-15 0.77 0.13 4 11 Maj
20I 90M 0.13 0.05 0.01 7.7 1E-14 0.77 0.13 7 16 Maj – Acc
24I 46L 0.18 0.03 0.02 7.5 6E-14 0.43 0.24 1 3 Maj
62V 93L 0.28 0.19 0.01 7.5 7E-14 0.47 0.40 24 47 Acc – Misc
Negative
correlations
30N 82A 0.00 0.08 0.00  82.5 0 0.00 0.00 — — Maj
82A 88D 0.00 0.06 0.00  53.5 0 0.00 0.00 — — Maj
24I 90M 0.00 0.04 0.00  37.7 0 0.01 0.00 — — Maj
36I 77I 0.03 0.17 0.00  31.9 0 0.07 0.06 — — Acc
30N 73S 0.00 0.05 0.00  27.4 0 0.00 0.00 — — Maj – Acc
30N 54V 0.01 0.07 0.00  22.9 0 0.02 0.01 — — Maj
30N 90M 0.02 0.09 0.00  18.4 0 0.08 0.02 — — Maj
73S 88D 0.00 0.04 0.00  17.9 0 0.00 0.00 — — Maj – Acc
16E 63P 0.00 0.02 0.00  17.3 0 0.11 0.00 — — Acc – Misc
64V 73S 0.01 0.06 0.00  15.4 0 0.01 0.03 — — Acc – Misc
aJ: Jaccard similarity coefficients; JRAND: expected value of the Jaccard similarity coefficient assuming Mut X and Mut Y occur independently based on a permutation procedure described in
Methods; JSE: the standard error of J; Z: (J   JRAND)/J SE. Mutation pairs are ordered by their Z statistic.
bBased on the number of persons with both mutations (Mut X and Mut Y) in whom an earlier sequence containing only Mut X or Mut Y: NX0!XY is the number in whom Mut X developed
first; N0Y!XY is the number in whom Mut Y developed first.
cMajor (Maj) indicates mutations in the protease substrate cleft or that directly reduce drug susceptibility. Accessory (Acc) indicates mutations that are commonly believed to reduce
susceptibility only in the presence of a major mutation or to compensate for the decreased replication associated with enzymes containing major mutations. Miscellaneous (Misc) includes
the remaining mutations, including some that are treatment-associated (see Methods) and others that are not. When both mutations belong to the same category, only one abbreviation
is shown.
doi:10.1371/journal.pcbi.0030087.t001
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HIV-1 Amino Acid CovariationSvicher and coworkers [6] and Cozzi-Lepri and coworkers in
independent datasets [7]. The conditional probabilities and
the temporal data columns show that each of the accessory
NRTI mutations consistently follows the Type I or II TAMs.
Among 12 pairs with a TAM and an accessory mutation, the
TAM occurred ﬁrst more often in all 12 pairs and was
preceded by the accessory mutation in only 6% of pairs. In
addition to the ﬁve accessory mutations in Table 2 (K43E,
E44D, V118I, H208Y, and D218E), other NRTI mutations that
consistently followed TAMs included the known treatment-
selected mutations T69D and T69N. Figure S2 plots the
relationship between the log of the ratio of the conditional
probability of two mutations versus the log of the ratio in
which two mutations develop, indicating that the conditional
dependence between mutations is highly correlated with the
order in which the mutations develop when they occur
together (r
2 ¼ 0.81, p , 0.001).
The Jaccard dissimilarity coefﬁcients associated with the
561 pairs of 34 mutations were used for a multidimensional
scaling. The mutations included in this analysis were the 23
positively associated mutations in Table 2 and 11 additional
clinically relevant NRTI-resistance mutations (K65R, A62V,
T69ins, L74I/V, V75M, Y115F, M184V, and K219R/E/N). Figure
2 plots the mutations along axes representing the ﬁrst two
principal components. The ﬁrst principal component ac-
counts for 13% of the total inertia and separates the TAMs
from the Q151M-associated mutations, whereas the second
principal component accounts for 9% of the total inertia and
separates the Type I and Type II TAMs. A62V, K65R, and
Y115F are mutations that cluster with Q151M but may also
occur with Type II (but not Type I) TAMs. D67N is a Type II
TAM that can also occur with Type I TAMs, and it therefore
occurs between Type I TAMs and Type II TAMs in terms of
the second principal component. The non-TAM mutations,
M184V and L74V, demonstrated no clustering with other
NRTI-associated mutations.
At several positions, there was sufﬁcient data to contrast
covariation patterns for different mutations (Table 2, Figure
2, and Table S3). The Type I TAM, T215Y, clustered with
other Type I TAMs, whereas the Type II TAM, T215F,
clustered with other Type II TAMs. K219Q/E were Type II
TAMs that cluster with other Type II TAMs. In contrast, two
less common mutations at this position (K219N/R) were
positively associated with Type I TAMs. T69D was associated
with both Type I and Type II TAMs, whereas T69N was
associated only with Type II TAMs. L74V was associated with
the NNRTI-resistance mutations L100I, K103N, and Y181C,
whereas L74I was associated with M41L. V75I was associated
with Q151M-associated mutations, whereas V75M was pos-
itively associated with the Type I TAMs.
Among 19,431 pairs of mutations in sequences from RT
inhibitor–naive persons, 41 pairs were signiﬁcantly associated
(family-wise error rate ,0.01; Table S4). However, all of the
positive associations among RT inhibitor–naive persons were
weaker (i.e., had a lower Z score) than the positive
associations among treated persons in Table 2.
Discussion
In this analysis of amino acid covariation in protease and
RT sequences from more than 7,000 persons infected with
HIV-1 subtype B viruses, we conﬁrmed several previously
reported patterns of amino acid covariation and identiﬁed
many new patterns of covariation. Multidimensional scaling
further organized many of the correlations into clusters of
co-occurring mutations. RT covariation was dominated by
the distinct clustering of the TAMs and Q151M-associated
mutations, and by the separation of the Type I and Type II
TAMs. Protease covariation was dominated by the clustering
of nelﬁnavir-associated mutations (D30N and N88D), two
main groups of PI-resistance mutations associated either with
V82A or L90M, and a newly identiﬁed cluster of the
mutations V32I, L33F, I47V, I50V, I54L/M, and L76V. This
new cluster of mutations is associated with decreased
susceptibility to all PIs, including the salvage therapy PIs
amprenavir and lopinavir and the recently approved PI
darunavir. Although none of the sequences in this study were
from patients who received darunavir, this drug is highly
similar to amprenavir and is affected by the same PI-
resistance mutations.
Previous studies of HIV-1 covariation have used either the
Pearson correlation for binomial random variables or mutual
information [3–6,8–10]. The correlation coefﬁcient is overly
sensitive to rare pairs of mutations because its statistical
signiﬁcance is based on a departure from equality between
the diagonal and off-diagonal products of a 232 contingency
table. In contrast, mutual information is insensitive to rare
pairs of mutations, approaching a high level only for
commonly occurring pairs of mutations. We therefore used
the Jaccard similarity coefﬁcient, which uses only those
sequences in which at least one of a pair of mutations is
present, and we assessed the signiﬁcance of this coefﬁcient
using a distribution based on the underlying data.
We also used a conservative correction for multiple
Figure 1. Multidimensional Scaling of 35 HIV-1 Protease Mutations
Includes the 22 mutations obtained from the mutation pairs with the
highest positive association (Table 1) in bold, and 13 additional clinically
relevant protease inhibitor resistance mutations (L10F, V32I, L33F, I47V,
I50V/L, F53L, I54L/M, Q58E, L76V, V82T, and N88S). The graph is a 2-D
projection of the distances among the 35 mutations, in which the
distance between any two mutations is measured by their Jaccard
dissimilarity coefficient among persons who have received at least one
protease inhibitor.
doi:10.1371/journal.pcbi.0030087.g001
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HIV-1 Amino Acid Covariationcomparisons (Holm’s method) because our analysis was not
designed to identify all covarying mutations but only those
with the strongest association. Without a correction for
multiple comparisons, 753 pairs of protease mutations from
PI-experienced persons and 2,061 pairs of RTI mutations
from RTI-experienced persons had a signiﬁcant Jaccard
similarity coefﬁcient at a p-value of 0.01 but with the Holm’s
correction, only 161 pairs of protease mutations and 327
Table 2. Forty Highest Positively Correlated RT Mutation Pairs and Ten Highest Negatively Correlated RT Mutation Pairs from RTI-
Experienced Persons
Correlations Mut X Mut Y Association
a P(YjX) P(XjY) Temporal Order
b Mutation
Classifications
c
JJ RAND JSE Zp N X0!XY N0Y!XY
Positive
correlations
41L 215Y 0.73 0.24 0.01 52.0 0 0.84 0.86 22 29 I
210W 215Y 0.60 0.17 0.01 37.2 0 0.94 0.62 16 64 I
41L 210W 0.59 0.17 0.01 36.5 0 0.61 0.94 59 10 I
70R 219Q 0.53 0.10 0.01 29.7 0 0.56 0.90 22 12 II
67N 70R 0.45 0.15 0.01 25.2 0 0.55 0.70 21 18 II
67N 219Q 0.41 0.11 0.01 23.6 0 0.43 0.88 9 6 II
118I 210W 0.39 0.10 0.01 22.0 0 0.71 0.47 3 61 I – Acc
116Y 151M 0.73 0.01 0.04 18.5 0 0.95 0.76 0 4 151
44D 210W 0.30 0.06 0.01 17.7 0 0.92 0.31 4 44 I – Acc
215F 219Q 0.36 0.06 0.02 17.7 0 0.65 0.44 0 21 II
41L 118I 0.29 0.12 0.01 16.7 0 0.32 0.78 102 4 I – Acc
70R 215F 0.29 0.07 0.01 16.6 0 0.31 0.78 27 5 II
210W 211K 0.33 0.18 0.01 15.7 0 0.73 0.38 23 48 I – Misc
44D 118I 0.30 0.05 0.02 15.3 0 0.68 0.34 15 13 Acc
118I 215Y 0.27 0.12 0.01 15.1 0 0.73 0.30 5 100 I – Acc
67N 118I 0.27 0.11 0.01 14.9 0 0.32 0.63 41 8 II – Acc
67N 210W 0.30 0.15 0.01 14.4 0 0.41 0.52 21 35 I – II
41L 44D 0.20 0.07 0.01 14.4 0 0.20 0.99 71 0 I – Acc
41L 67N 0.34 0.20 0.01 14.4 0 0.45 0.57 50 28 I – II
44D 215Y 0.21 0.07 0.01 14.3 0 0.98 0.21 6 74 I – Acc
67N 69D 0.20 0.06 0.01 13.6 0 0.21 0.85 14 1 II – Misc
67N 215F 0.22 0.08 0.01 13.5 0 0.24 0.75 26 1 II
208Y 210W 0.20 0.05 0.01 12.8 0 0.81 0.21 4 41 I – Acc
123E 177E 0.25 0.12 0.01 12.7 0 0.36 0.45 13 7 Misc
75I 116Y 0.57 0.01 0.04 12.6 0 0.76 0.70 1 2 151
77L 116Y 0.58 0.01 0.05 12.5 0 0.77 0.70 0 1 151
43E 210W 0.19 0.04 0.01 12.4 0 0.86 0.19 2 30 I – Acc
77L 151M 0.52 0.01 0.04 12.2 0 0.81 0.60 0 3 151
69N 70R 0.18 0.04 0.01 12.0 0 0.83 0.19 3 19 II – Misc
44D 208Y 0.26 0.03 0.02 11.7 0 0.37 0.48 6 5 Acc
218E 219Q 0.21 0.04 0.01 11.7 0 0.68 0.23 0 28 II – Acc
75I 151M 0.49 0.01 0.04 11.7 0 0.78 0.57 0 6 151
75I 77L 0.54 0.01 0.05 11.5 0 0.68 0.72 0 1 151
211K 215Y 0.37 0.26 0.01 11.5 0 0.49 0.59 69 43 I – Misc
60I 67N 0.21 0.09 0.01 11.5 0 0.59 0.24 7 31 II – Misc
44D 67N 0.17 0.06 0.01 11.4 0 0.72 0.19 5 30 II – Acc
118I 208Y 0.20 0.04 0.01 11.3 0 0.23 0.58 14 6 Acc
41L 208Y 0.15 0.05 0.01 11.3 0 0.15 0.94 55 2 I – Acc
67N 215Y 0.30 0.20 0.01 11.2 0 0.53 0.41 17 57 I – II
214L 219Q 0.21 0.07 0.01 11.2 0 0.37 0.33 12 9 II – Misc
Negative
correlations
210W 214L 0.01 0.09 0.00  50.2 0 0.01 0.02 — — I – Misc
214L 215Y 0.01 0.10 0.00  48.8 0 0.04 0.01 — — I – Misc
44D 215F 0.00 0.04 0.00  35.9 0 0.00 0.00 — — II – Acc
44D 214L 0.00 0.05 0.00  34.6 0 0.01 0.00 — — Acc – Misc
65R 215Y 0.00 0.02 0.00  33.7 0 0.01 0.00 — — I – II
41L 214L 0.03 0.11 0.00  25.8 0 0.03 0.10 — — I – Misc
70R 210W 0.04 0.13 0.00  24.5 0 0.07 0.07 — — I – II
162C 166R 0.00 0.05 0.00  24.1 0 0.00 0.01 — — Misc
121H 123E 0.00 0.02 0.00  23.4 0 0.01 0.00 — — Misc
122E 123E 0.06 0.16 0.00  22.6 0 0.09 0.13 — — Misc
aJ: Jaccard similarity coefficients; JRAND: expected value of the Jaccard similarity coefficient assuming Mut X and Mut Y occur independently based on a permutation procedure described in
Methods; JSE : the standard error of J; Z: (J   JRAND)/J SE. Mutation pairs are ordered by their Z statistic.
bBased on the number of persons with both mutations (Mut X and Mut Y) in whom an earlier sequence containing only Mut X or Mut Y: NX0!XY is the number in whom Mut X developed
first; N0Y!XY is the number in whom Mut Y developed first.
cI: Type I TAMs; II: Type II TAMs; Acc: accessory NRTI-resistance mutations; 151: Q151M-associated mutations; Miscellaneous (Misc) includes the remaining mutations, including some that
are treatment associated (see Methods) and others that are not. When both mutations belong to the same category, only one abbreviation is shown.
doi:10.1371/journal.pcbi.0030087.t002
PLoS Computational Biology | www.ploscompbiol.org May 2007 | Volume 3 | Issue 5 | e87 0840
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family-wise error rate of 0.01.
Covariation between two mutations may result from the
shared inheritance of the mutations from a founder virus,
from a shared evolutionary pressure (e.g., an antiretroviral
drug) that independently selects for each mutation, or from a
functional dependency between the mutations. In our
analysis, covariation was unlikely to result from shared
inheritance because the most strongly covarying mutations
occurred solely among treated HIV-1 isolates, consistent with
the repeated selection of the correlated mutations in many
different isolates as a result of selective drug pressure rather
than the inheritance of the correlated mutations from a small
number of ancestral viruses.
However, the possibility that many of the covarying
residues resulted from similar selective pressures rather than
from functional dependency cannot be excluded. For
example, it is possible that some pairs of covarying protease
amino acids result from the selective pressure of the same PI
or possibly pair of PIs. Shared selective pressure is a possible
explanation for why covarying mutations are not necessarily
close to one another in tertiary structures (Figure S3) [4]. An
analysis of covariation that controls for treatment history
would be better able to distinguish functional dependency
from shared selective pressure. However, for most PIs and
NRTI combinations, insufﬁcient data are available for such
an analysis. Identifying similar patterns of covariation in one
or more independent lineages (e.g., other non-B subtypes)
would also provide additional independent evidence for
functional dependency.
Our examination of conditional dependency between
mutation pairs, the temporal order in which mutations
occur, and the relationship between these two types of data
provided new insights into the evolution of protease and RT
in persons receiving antiretroviral therapy. A strong positive
relationship between the conditional dependency ratio of
two mutations and the order in which the mutations occur
would represent the most parsimonious mechanism for HIV-
1 to develop multiple mutations (i.e., the mutation that
occurs more often in a pair of mutations would be on average
more likely to occur ﬁrst). Nonetheless, we found that the
positive relationship between conditional dependency and
the order of mutation occurrence was stronger for covarying
RT (r
2 ¼ 0.81) compared with protease (r
2 ¼ 0.56) mutation
pairs. This suggests that the number of mutational steps
required to develop multiple PI-resistance mutations may be
greater on average than that required for developing the
same number of multiple NRTI-resistance mutations.
We also found that accessory NRTI-resistance mutations
nearly always followed primary NRTI-resistance mutations
(particularly the TAMs). In contrast, the commonly recog-
nized accessory PI-resistance mutations were as likely to
precede as to follow major PI-resistance mutations. This
frequent precedence of accessory PI-resistance mutations
results in part from the fact that many of the accessory PI-
resistance mutations are polymorphic and therefore present
prior to the start of therapy. However, this alone does not
explain the marked dependency of some major mutations on
polymorphic accessory PI-resistance mutations that occur
only at low levels in untreated persons.
The strong positive relationship between conditional
probabilities and temporal data that we describe support
the validity of previous research, which used cross-sectional
data to infer mutational pathways [11] and causality [12,13].
Our results also suggest that there is a complex process
underlying the order in which major and accessory PI-
resistance mutations develop during PI therapy, and that the
designation of major PI-resistance mutations as primary and
accessory PI-resistance mutations as secondary often refers
only to their roles in causing resistance and not to the order
in which they develop.
Materials and Methods
Virus sequence data. Sequences included HIV-1 subtype B RT and
protease sequences from published studies in the Stanford HIV Drug
Resistance Database (http://hivdb.stanford.edu) [14]. For patients with
more than one sequence, only the latest sequence obtained while
receiving treatment was analyzed. For each gene, separate analyses
were done for the sequences from treatment-experienced and
treatment-naive individuals.
RT positions 1–240 and protease positions 1–99 were analyzed.
Mutations were deﬁned as differences from the consensus wild-type
subtype B amino acid reference sequence (http://hivdb.stanford.edu/
pages/asi/releaseNotes/index.html). For each pair of mutations (X, Y),
the numbers of sequences containing both mutations (X and Y), only
one mutation (X or Y), or neither mutation (not X, not Y) were
counted and used to populate a contingency table. Sequences
containing mixtures at either of the two positions were excluded
from analysis of that pair of positions.
Antiretroviral treatment–selected mutations were deﬁned based
on the results of a previous study, as mutations that were signiﬁcantly
more common in treated than untreated persons after adjusting for
multiple comparisons [15]. PI-selected mutations included L10I/V/F/
R, V11I, K20R/M/I/T, L23I, L24I, D30N, V32I, L33F/I, E34Q, E35G,
M36I/V, K43T, M46I/L/V, G48V/M, I50V/L, F53L, I54V/M/L/T/A/S,
K55R, Q58E, L63P, I66F, C67F, A71V/T/I, V72L, G73S/T/C/A, T74A/P/
S, L76V, V77I, V82A/T/F/S/L/M, I84V/A/C, I85V, N88D/S/T/G, L89V,
Figure 2. Multidimensional Scaling of 34 HIV-1 Reverse Transcriptase
Mutations
Includes the 23 mutations obtained from the mutation pairs with highest
positive association (Table 2) in bold, and 11 additional clinically relevant
nucleoside RT inhibitor resistance mutations (K65R, A62V, T69ins, L74I/V,
V75M, Y115F, M184V, and K219R/E/N). The graph is a 2-D projection of
the distances among the 37 mutations, in which the distance between
any two mutations is measured by their Jaccard dissimilarity coefficient
among persons who have received at least one nucleoside RT inhibitor.
doi:10.1371/journal.pcbi.0030087.g002
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HIV-1 Amino Acid CovariationL90M, T91S, Q92R/K, I93L, and C95F. Several PI-resistance muta-
tions—particularlythosethatoccurinthesubstratecleftorthathavea
major impact on drug susceptibility—are considered major PI-
resistance mutations [2,16]. For the purposes of this study, we deﬁned
mutationsatpositions24,30,32,46,47,48,50,53,54,76,82,84,88,and
90 as being major PI-resistance mutations. Several PI-resistance
mutations—including several that are polymorphic in untreated
persons—are commonly considered accessory drug resistance muta-
tions that either compensate for the decreased replication associated
with many of the major mutations or that reduce drug susceptibility
furtherwhenpresentwithamajormutation.Mutationsatpositions10,
20, 33, 36, 58, 63, 71, 73, 74, 77, and 93 are usually considered to be
accessory mutations. Little attention has been given to the remaining
PI-selected mutations, and for the purposes of this paper, we leave
themunclassiﬁedwithrespecttothedesignationsmajorandaccessory.
NRTI-selected mutations included T39A, M41L, K43E/Q/N, E44D/
A, A62V, K65R, D67N/G/E, T69D/N/S/insertion, K70R, L74V/I, V75I/M/
T/A, F77L, V90I, K104N, Y115F, F116Y, V118I, Q151M, M184V/I,
E203K, H208Y, L210W, T215Y/F/D/C/E/S/I/V, D218E, K219Q/E/N/R,
H221Y, K223Q, and L228H/R. These mutations included the Type I
TAMs M41L, L210W, and T215Y, and the Type II TAMs D67N, K70R,
T215F, and K219Q/E [7]. Recently described accessory NRTI
mutations included T39A, K43E/Q/N, E44D/A, V118I, E203K, H208,
D218E, H221Y, K223Q, and L228H/R [3,6,17]. Q151M-associated
mutations included A62V, V75I, F77L, F116Y, and Q151M [18,19].
NNRTI-selected mutations included A98G, L100I, K101E/P/N/H,
K103N/S, V106A/M, V108I, V179D/E, Y181C/I/V, Y188L/C/H, G190A/S/
E/Q, P225H, F227L, M230L, P236L, and K238T.
Pairwise correlation. We used the Jaccard similarity coefﬁcient (J)
to assess covariation among protease and RT mutations. For a given
pair of mutations X and Y, the Jaccard similarity coefﬁcient is
calculated as J ¼ NXY /(NXY þ NX0 þ N0Y) where NXY represents the
number of sequences containing X and Y, NX0 represents the number
of sequences containing X but not Y, and N0Y represents the number
of sequences containing Y but not X. This coefﬁcient represents the
probability of both mutations occurring together when either
mutation occurs and, therefore, does not inﬂate the correlation
between two mutations that may appear correlated by other measures
when both mutations are nearly always absent.
To test whether observed Jaccard similarity coefﬁcients were
statistically signiﬁcant, the expected value of the Jaccard similarity
coefﬁcients (JRAND) and its standard error (JSE)a s s u m i n gt w o
mutations (X and Y) occur independently were calculated for each
pair of mutations. JRAND was calculated as the mean Jaccard similarity
coefﬁcient after 2,000 random rearrangements of the X or Y vector
(containing 0 or 1 for presence or absence of a mutation,
respectively). JSE was calculated using a jackknifed procedure, which
removed one sequence at a time, repeatedly for each sequence. The
standardized score Z, Z ¼ (J   JRAND)/JSE, indicates a signiﬁcant
positive association (Z . 2.56) or a signiﬁcant negative association (Z
,  2.56) at an unadjusted p , 0.01.
Holm’s method was used to control the family-wise error rate for
multiple hypothesis testing [20]. The p-values of observed Jaccard
similarity coefﬁcients for all pairs of mutations were ranked in
descending order. Starting from the smallest p (rank r ¼n, where n is
the number of pairs), we compared each p of rank r with a
signiﬁcance cutoff of 0.01 / r as long as pr   0.01 / r. All p-values
from pr...pn were considered to be statistically signiﬁcant.
To deal with contingency tables containing 0 for NXY (potentially
leading to Z scores of  ‘), we generated a conservative nonzero
approximation of JSE using the following procedure. Given a dataset
of n sequences, x with mutation X and y with mutation Y,w e
computed the probability of both mutations (PXY), mutation X but
not Y (PX0), mutation Y but not X (P0Y), and neither mutation (P00)
under the null hypothesis of independence by PXY¼(x/n )3(y / n), PX0
¼(x / n)3(y / n)/n ,P0Y¼(n x)/n3(y / n) and P00¼1 PXY PX0 P0Y.
These probabilities were used to create 200 two-by-two contingency
tables with cells containing randomly distributed numbers adding up
to 20,000 based on the null hypothesis probabilities of independence.
Multidimensional scaling. Given the matrix of dissimilarity
coefﬁcients (1   Jaccard similarity coefﬁcient) for a list of mutations
(X1, X2, ..., Xn), multidimensional scaling was used to construct points
in 2-D space such that the Euclidean distances between these
points approximate the entries in the dissimilarity matrix [21]. For
a given k, it computes points X1, X2, ..., Xn in 2-D space such that
S ¼
P
i;jðdistðXi;XjÞ dijÞ
2 is minimized where dist(Xi, Xj) is the
Euclidean distance between Xi and Xj and dij is the dissimilarity
between Xi and Xj in the matrix D. This was performed using the R
function cmdscale (classical multidimensional scaling).
Multidimensional scaling captures the inertia in a dataset in terms
of a set of variables (or principal components) that deﬁne a
projection that encapsulates the maximum amount of inertia in a
dataset and is orthogonal (and therefore uncorrelated) to the
previous principal component. Using the ﬁrst and second principal
components, we summarized the relationship among mutations in a
graphical model, placing pairs of mutations with low Jaccard
dissimilarity coefﬁcients close together and mutations with high
Jaccard dissimilarity coefﬁcients far apart.
Supporting Information
Figure S1. Relationship between Conditional Probability and Order
of Occurrence within Pairs of Covarying Protease Mutations
The relationship between the log of the ratio of the conditional
probability of two protease mutations and the log of the ratio in
which mutation develops ﬁrst. A total of 38 protease mutation pairs
from Table 1, of which the sum of (X,0 ! X,Y) and (0,Y ! X,Y)  5,
the count of (X,0 ! X,Y) or (0,Y ! X,Y) is not zero, were plotted.
Found at doi:10.1371/journal.pcbi.0030087.sg001 (22 KB PDF).
Figure S2. Relationship between Conditional Probability and Order
of Occurrence within Pairs of Covarying RT Mutations
The relationship between the log of the ratio of the conditional
probability of two RT mutations and the log of the ratio in which
mutation develops ﬁrst. A total of 31 RT mutation pairs from Table 2,
of which the sum of (X,0 ! X,Y) and (0,Y ! X,Y)  5, the count of (X,0
! X,Y) or (0,Y ! X,Y) is not zero, were plotted.
Found at doi:10.1371/journal.pcbi.0030087.sg002 (22 KB PDF).
Figure S3. Structural Locations and Distances For Three Sets of
Covarying Protease Mutations
Locations of residues present in the three most relevant clusters of
PI-resistance mutations superimposed on the crystallographic struc-
ture of wild-type HIV-1 (1HPV.pdb): L24, M46, I54, and V82 (A); M46,
G73, I84, and L90 (B); and V32, L33, I47, I50, I54, and L76 (C). Each
panel shows the wild-type residues superimposed on the substrate
cleft surface of the protease monomer. The shortest interatomic
distances between selected residues are shown. Cluster A usually
contains the mutations L24I, M46L . M46I, I54V, and V82A. Cluster
B usually contains the mutations M46I, G73S, I84V, and L90M.
Cluster C usually contains the mutations V32I, L33F, I47V, I50V, I54L
. I54M, and L76V. The cluster consisting of mutations at positions 30
and 88 is not shown, as it is associated with resistance to a single PI
(nelﬁnavir) rather than to multiple PIs.
Found at doi:10.1371/journal.pcbi.0030087.sg003 (2.0 MB TIF).
Table S1. 161 Highly Correlated Protease Mutation Pairs from PI-
Experienced Persons
Found at doi:10.1371/journal.pcbi.0030087.st001
Table S2. Highly Correlated HIV-1 Subtype B Protease Mutation
Pairs from PI-Naive Persons
Found at doi:10.1371/journal.pcbi.0030087.st002
Table S3. 327 Highly Correlated Protease Mutation Pairs from RTI-
Experienced Persons
Found at doi:10.1371/journal.pcbi.0030087.st003
Table S4. Highly Correlated HIV-1 Subtype B RT Mutation Pairs
from RTI-Naive Persons
Found at doi:10.1371/journal.pcbi.0030087.st004
Text S1. Accession Numbers
Found at doi:10.1371/journal.pcbi.0030087.sd001
Accession Numbers
The11,355GenBank(http://www.ncbi.nlm.nih.gov/Genbank)accession
numbers of the sequences used in this study are provided in Text S1.
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